Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Launched by FUDAN UNIVERSITY · Feb 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of immune checkpoint inhibitors (ICIs) in treating solid tumors, which are cancers that form in tissues such as organs. The trial includes patients of all ages (18 and older) who have been diagnosed with a solid tumor and are receiving treatment with ICIs. The goal is to understand how effective and safe these treatments are in real-life situations, outside of clinical trials.

To participate, individuals must be at least 18 years old and have a confirmed diagnosis of solid tumor cancer. They should also agree to participate and be able to understand the study's information. However, those under 18, with certain blood cancers, benign tumors, or conditions that could affect their ability to follow the study guidelines cannot take part. Participants can expect to share their experiences with ICIs, which may help doctors make better decisions about cancer treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age at least 18 years.
• • Pathologically confirmed diagnosis of a solid tumor cancer.
• • Patients receiving treatment with immune checkpoint inhibitors.
• • Ability to understand and willingness to provide the informed consent.
• Exclusion Criteria:
• • Age \< 18 years.
• • Patients with hematological malignancies or solid benign tumors.
• • Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.